Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10388122 | 0.87 | ESR1 (0.64) | L3MBTL1ESR1ESR2KMT2A | |
| SCHEMBL27610226 | 0.87 | ESR1 (0.47) | L3MBTL1ESR1ESR2KMT2ATDP1 | |
| SCHEMBL631468 | 0.85 | ESR1 (0.46) | L3MBTL1ESR1ESR2KMT2AALDH1A1 | |
| SCHEMBL20826234 | 0.85 | L3MBTL1 (0.57) | L3MBTL1ESR1ESR2KMT2APOLB | |
| SCHEMBL3168058 | 0.85 | KMT2A (0.59) | ESR1ESR2KMT2AALDH1A1LMNA | |
| SCHEMBL20274587 | 0.85 | KMT2A (0.59) | ESR1ESR2KMT2AALDH1A1LMNA | |
| SCHEMBL8531591 | 0.84 | ESR1 (0.53) | L3MBTL1ESR1ESR2KMT2AALDH1A1 | |
| SCHEMBL5361583 | 0.83 | ALDH1A1 (0.49) | L3MBTL1ESR1ESR2KMT2AALDH1A1 | |
| SCHEMBL5361574 | 0.83 | ALDH1A1 (0.49) | L3MBTL1ESR1ESR2KMT2AALDH1A1 | |
| SCHEMBL20826431 | 0.81 | KMT2A (0.44) | L3MBTL1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200216445-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| WO-2019055877-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216445-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | L3MBTL1 669/4885ESR1 3679/4885ESR2 1958/4885 |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | L3MBTL1 669/4885ESR1 3679/4885ESR2 1958/4885 |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | L3MBTL1 669/4885ESR1 3679/4885ESR2 1958/4885 |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | L3MBTL1 669/4885ESR1 3679/4885ESR2 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.